Table 2. Univariate Cox regression of clinical variables and radiological features for overall survival in LR and TACE group.
| LR | TACE | |||||
|---|---|---|---|---|---|---|
| Factors | n | HR (95% CI) | P | n | HR (95% CI) | P |
| Sex female | 12 | reference | 0.843 | 4 | reference | 0.269 |
| male | 74 | 1.103 (0.419–2.904) | 40 | 30.802 (0.071–13345.010) | ||
| Age | 86 | 0.981 (0.952–1.012) | 0.225 | 44 | 1.016 (0.987–1.045) | 0.281 |
| BCLC stage* C | 10 | Reference | 0.117 | 6 | Reference | 0.163 |
| AB | 76 | 0.427 (0.147–1.237) | 38 | 0.380 (0.097–1.478) | ||
| Maximum diameter | 86 | 1.005 (0.994–1.016) | 0.337 | 44 | 0.998 (0.987–1.008) | 0.660 |
| Cirrhosis positive | 28 | Reference | 0.388 | 10 | Reference | 0.425 |
| negative | 58 | 0.704 (0.318–1.561) | 34 | 0.753 (0.328–1.624) | ||
| Child-Pugh Class B | 2 | Reference | 0.940 | 3 | Reference | 0.590 |
| A | 84 | 1.080 (0.146–7.996) | 41 | 1.518 (0.333–6.921) | ||
| Hepatitis HBV | 31 | Reference | 0.557 | 11 | Reference | 0.321 |
| negative | 55 | 1.256 (0.587–2.689) | 33 | 0.570 (0.188–1.729) | ||
| AFP (ng/ml) >400 | 22 | Reference | 0.522 | 16 | Reference | 0.802 |
| <25 | 32 | 1.018 (0.394–2.633) | 15 | 0.906 (0.313–2.624) | ||
| 25∼400 | 32 | 1.593 (0.603–4.209) | 13 | 1.349 (0.412–4.420) | ||
| Post-TACE yes | 44 | Reference | 0.791 | - | All received post-TACE | - |
| no | 42 | 0.904 (0.429–1.906) | ||||
| Post-ablation yes | 8 | Reference | 0.164 | 16 | Reference | 0.709 |
| no | 78 | 4.139 (0.560–30.580) | 28 | 1.187 (0.482–2.924) | ||
| Capsule integral | 14 | Reference | 0.396 | 14 | Reference | 0.125 |
| absence | 9 | 1.129 (0.206–6.181) | 14 | 3.475 (1.049–11.510) | ||
| not integral | 63 | 1.955 (0.667–5.727) | 16 | 1.917 (0.619–5.933) | ||
| Shape invasive | 29 | Reference | 0.814 | 23 | Reference | 0.108 |
| non-invasive | 57 | 0.911 (0.419–1.982) | 21 | 0.469 (0.186–1.182) | ||
| Corona† positive | 40 | Reference | 0.057 | 15 | Reference | 0.367 |
| negative | 46 | 0.478 (0.224–1.021) | 29 | 0.650 (0.255–1.657) | ||
| Mosaic positive | 67 | Reference | 0.144 | 31 | Reference | 0.150 |
| negative | 19 | 0.485 (0.184–1.280) | 13 | 2.032 (0.773–5.336) | ||
| Node in Node | All negative | All negative | ||||
| Enhance region >75% | 67 | Reference | 0.894 | 38 | Reference | 0.223 |
| 0%-25% | - | - | - | - | ||
| 25%–50% | 5 | 0.704 (0.095–5.235) | 2 | 2.478 (0.300–20.433) | ||
| 50%–75% | 14 | 1.158 (0.438–3.065) | 4 | 3.720 (0.768–18.020) | ||
| Differentiation poor | 43 | Reference | 0.713 | Not available in TACE group | - | |
| moderate | 32 | 1.028 (0.541–1.863) | ||||
| moderate-poor | 11 | 0.725 (0.355–1.748) | ||||
| MI positive | 46 | Reference | 0.452 | Not available in TACE group | - | |
| negative | 40 | 0.703 (0.297–1.742) | ||||
Dash indicated no data identified; *in this study, presence of vascular invasion was represented by BCLC stage (B: absence; C, presence); †factors in the univariate analyses with a P <0.10 entered multivariate analyses; # All LR patients had assessments of microvascular invasion, whereas it was not available in TACE patients.
LR: liver resection; TACE: transcatheter arterial chemoembolization; HR: hazard ratio; BCLC: Barcelona Clinic Liver Cancer; AFP: alpha fetoprotein; MI: microvascular invasion;